NCT07174401

Rocklatan Retinal Perfusion OCT Study

Rocklatan Trial With Optical Coherence Tomography Study of Retinal Perfusion

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Oregon Health and Science University · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.	The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.
DEVICE	Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.	One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-12-01
• Completion: 2027-10-01
• First posted: 2025-09-16
• Last updated: 2025-12-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study